Sven Francque, EASL ILC 2021: Lanifibranor NATIVE Subgroup Analysis
Prof. Dr Sven Francque (University of Antwerp, Belgium) kindly spoke with us about the additional analysis of the phase 2b NATIVE trial investigating lanifibranor in patients with NASH.
His presentation entitled ‘Lanifibranor therapy improves markers of lipid metabolism, insulin resistance, liver injury and fibrosis in patients with NASH and F2 and F3 fibrosis stages: a subgroup analysis of the phase 2b NATIVE study’ was given at EASL ILC 2021, 23-26 June.
- What is the rationale for the use of lanifibranor therapy in patients with NASH? (0:10)
- Could you briefly describe the aims, design and patient population of the NATIVE trial? (1:03)
- What were the effects of lanifibranor therapy on histological endpoints, and how did findings in the F2/F3 population compare with those of the overall patient population? (1:51)
- What effect did lanifibranor have on markers of liver injury, inflammation and fibrosis? (2:27)
- What was the safety and tolerability profile of lanifibranor? (3:27)
Disclosures: Prof. Dr Sven Francque has served as a speaker for AbbVie, Allergan, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Genentech, Genfit, Gilead, Intercept Pharmaceuticals, Inventiva, Novartis, NGM Bio, NovoNordisk and Roche. He has also acted as a consultant for AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Genentech, Genfit, Gilead, Intercept Pharmaceuticals, Inventiva, Novartis, NGM Bio, Novo Nordisk and Roche.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the EASL ILC 2021, 23-26 June.
Share this Video
Related Videos In Liver Disorders
Peter Ferenci, EASL ILC 2022: Wilson’s disease – diagnosis and treatment
Wilson’s disease is a rare, genetic disorder characterized by the accumulation of excess copper in vital organs such as the liver and brain. Damage caused by the excess copper build-up can lead to symptoms of liver and neurological diseases. In this touchENDOCRINOLOGY interview, we speak with Prof. Peter Ferenci (Medical University of Vienna, Vienna, Austria) […]
Camilla Dalby Hansen, EASL ILC 2022: Non-calorie restricted, low carbohydrate, high fat diet for NAFLD in T2DM
touchENDOCRINOLOGY spoke with Camilla Dably Hansen (Odense Hospital, Denmark) about the findings from the recent 6-month randomised controlled trial investigating the impact of a non-calorie restricted, low carbohydrate, high fat diet on nonalcoholic fatty liver disease (NAFLD) activity score (NAS) and HbA1c in patients with type 2 diabetes (T2DM). The abstract entitled ‘A non-calorie restricted […]
Aleksander Krag, EASL 2022: International Liver Congress Update
We caught up with the European Association for the Study of the Liver (EASL) Vice-Secretary, Prof. Aleksander Krag, to discuss the upcoming International Liver Congress (ILC) and what to expect. At ILC 2022 they will be bringing back face-to-face meetings in a new model, reshaping the scientific programme, offering a fresh experience, merging the very best […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!